Sign in
SuspendedNo phase

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Rockville, United StatesSee the site
Trial code
Status
Suspended
People taking part
2,400 people, planned
Started
7 Feb 2017
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • Biospecimen Collection
  • Laboratory Biomarker Analysis
Record updated
13 May 2026
Why it stopped
Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and filling out necessary paperwork before taking the steps to forma

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients with either:; Histologically confirmed invasive carcinoma or multiple myeloma OR; Clinical diagnosis of carcinoma or multiple myeloma OR; Suspected clinical diagnosis of multiple myeloma
  • Patients with one of following tumor types and age ranges:; Breast cancer diagnosis at ages 18-45; Colon cancer diagnosis at ages 18-55; Kidney cancer at diagnosis at ages 18-50 (American Indian or Alaska Native [AIAN] and non-Hispanic Whites [NHW] only); Liver cancer diagnosis at ages 18-55; Prostate cancer diagnosis at ages 18-55; Multiple myeloma diagnosis at ages 18-50
  • Patients whose tumor specimen was collected or will be collected during one of the following routine procedures:; Surgery to remove cancer OR; Routine biopsy procedures performed to confirm a histologic diagnosis OR; Routine biopsy procedure performed to obtain additional tumor material for routine prognostic or predictive biomarkers OR; Routine procedure to place a vascular access device prior for systemic therapy
  • Patients who have received no therapy for their cancer other than surgery, irrespective of stage
  • Collection of specimens from living patients:; Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol
  • Collection of specimens from deceased patients:; Banked tissue samples and/or banked biologic fluid specimens of deceased patients may be used as long as all samples or specimens are properly de- identified prior to submission
  • Sites must use the Central Institutional Review Board for the National Cancer Institute (NCI CIRB)

Who cannot take part

  • Prior systemic therapy or radiation therapy for their malignancy
  • Patients who do not meet criteria for an early onset malignancy
  • Patient refused consent for use of tissue for research activities included in the Early Onset Malignancies Initiative
  • A diagnosis of a synchronous invasive malignancy
  • Patients with a history of invasive cancer or hematologic malignancy in preceding 5 years
  • Tumor does not meet quality metrics

Where in United States

  • National Cancer Institute Division of Cancer PreventionRockville, United States

About the trial

What the trial wants to find out

This research trial studies how well biospecimen collection works in identifying genetic changes in patients with breast, prostate, colorectal, liver, or kidney cancer or multiple myeloma undergoing surgery. Studying samples collected during surgery may add to the understanding of cancer by looking for the genetic changes that cause early cancer onset in people of certain racial and ethnic groups.

The group in the trial

  • Ancillary-correlative (biospecimen collection)

    Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.

    Treatment: Biospecimen Collection and Laboratory Biomarker Analysis

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Early Onset Malignancies Initiative (EOMI): Molecular Profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate Among Racially and Ethnically Diverse Populations
Record updated
13 May 2026